Onco-Innovation

The translation of new discoveries in the laboratory into better treatments for patients is a priority for the Cambridge Cancer Centre. Onco-innovation provides a collaboration point for our colleagues in the pharmaceutical industry as well as members from University departments in the physical sciences. It is the combination of disciplines that provide the greatest opportunity for innovation and novel approaches.

Collaborations between biological and physical scientists
Single cell genomics

Physical scientists are working closely with biological and clinical scientists to gain greater understanding of interactions that occur at the single cell level using novel sequencing, imaging, and nanotechnologies. Examination of diseases at single cell resolution, both at diagnosis and after treatment, will transform the practice of molecular medicine by improving the quality of patient diagnosis, refining treatment options, monitoring the response to treatment, and detecting the emergence of resistance to treatment. Cambridge scientists have been at the forefront of basic research in single cell expression profiling and the analysis of circulating tumour DNA, as well as setting up local biotech ‘spinout’ companies that develop novel single cell technologies.

MRC funding has enabled the creation of the Cambridge Single Cell Analysis Clinical Core Facility, a new shared core facility for single cell analysis that will serve all major molecular medicine programmes in Cambridge: cancer, neurosciences, immunity and inflammation, infectious diseases, stem cell and regenerative medicine, metabolic medicine and experimental therapeutics. The facility will work closely with strategic partners in the Cambridge area such as the Babraham Institute, Wellcome Trust Sanger Institute, the European Bioinformatics Institute, the MRC Laboratory for Molecular Biology and major pharmaceutical and biotechnology companies to bring their different capabilities to bear on clinical research challenges.

Training and Innovation

A major goal is to support the development of cross-disciplinary laboratories to explore, invent and develop novel technologies and new ways to analyse data. Training programmes in Chemical Biology, Computational Biology, and Cambridge Cancer Centre studentships require this as part of the research project. The aim is to bring together researchers from the physical and life sciences, mathematics, statistics and computer science, engineering and clinical medicine working together in integrated laboratories on the hospital site. These interactions will serve as an ‘incubator’ for ideas to be generated and evaluated and will facilitate high risk, cross-disciplinary collaborations.

Pump Priming Grants

The Cambridge Cancer Centre promotes and supports interdisciplinary research through the funding of pump priming grants. The grants are to support cross disciplinary activities between different groups with a focus on cancer. This provides support for novel and high risk projects with a clear connection to Cancer. The titles of recent grants are below:

  • The role of fumarate as epigenetic modifier in renal cancer
  • Development of stapled peptides to inhibit K-Ras proteins
  • Generation and Characterization of Liver Cancer in vitro
  • Organoid Models Development of Novel Nanocarriers for Cancer Theranostics using DNA Nanotechnology
  • Investigating the morphological & proliferative heterogeneity of human glioblastoma by temporal microscopy-based phenotyping
  • The mechanics of glioblastoma Cancer in 4D: high-throughput sequencing and lineage tracing of tumours in situ
  • Voltage control of oncogene function using next-generation super-resolution nanoscopy
Pharmaceutical collaborations

Cambridge is a hub for innovation and enterprise with a vibrant biotechnology and pharmaceutical industry, hosting over 160 life science spin-offs and established businesses. The Cambridge Cancer Centre is building a Therapeutics Consortium, which will connect the intellectual know-how of several large academic institutions with the drug-developing potential of the pharmaceutical industry to deliver better drugs to the clinic.

Cancer Research UK has teamed up with Cambridge-based research company MedImmune to form the newly-opened CRUK-MedImmune Alliance Laboratory with the aim of accelerating the translation of cancer research into potential new drugs. AstraZeneca is due to open its new global headquarters in Cambridge in 2017. The new building on the Biomedical Campus, near Addenbrooke’s Hospital and many world-renowned research institutes, will house 2000 staff.

Principal investigators and consultants

  • All members
  • Group leaders
  • Clinical consultants
University of Cambridge
Department of Chemistry
Fragment based drug discovery Mechanistic enzymology research on reactions in microdroplets in microfluidics, with potential applications...
PI:
Y
CC:
N
Cambridge University Hospitals NHS Foundation Trust
Molecular Malignancy Laboratory, HODS
Solid and Liquid Tumour Analysis by Next Generation Sequencing Personalilsed Medicine
PI:
N
CC:
N
Microsoft Research
Multi-omics metabolic models Optimization
PI:
N
CC:
N
Functional Genomics of Breast Cancer. Development and utilisation of Patient derived tumour models in therapeutic research.
PI:
N
CC:
N
University of Cambridge
Department of Chemistry
My group's research interests lies under the broader field of Chemical Biology. In particular, we are developing novel site-specific and...
PI:
Y
CC:
N
University of Cambridge
Department of Physics
Understanding the mechanisms underlying cancer extravasation is of fundamental importance in developing therapeutic targets for the...
PI:
N
CC:
N
University of Cambridge
Core Pharmacokinetics/Bioanalytics
Development and validation of quantitative LC-MS/MS methods for the analysis small molecules and  metabolites/biomarkers in biological...
PI:
N
CC:
University of Cambridge
Department of Chemistry
The aim of my research is to build ruthenium organometallic groups into validated, medicinal compounds such that the ligand efficiency of...
PI:
Y
CC:
N
European Bioinformatics Institute
Functional genomics research
High throughput (microarray, sequencing) data analysis. Data integration. Cell cycle. I am in charge of running and developing the...
PI:
Y
CC:
N
Cancer Research UK Cancer Research Technologies (CRT)
Drug discovery at CRT working in medicinal chemistry to deliver small molecule inhibitors of cancer targets.
PI:
N
CC:
N
University of Cambridge
Department of Materials Science and Metallurgy
My research concerns medical materials. We design, produce and characterise materials designed for use within the body, materials for...
PI:
Y
CC:
N
AstraZeneca
Translational Science - Oncology Innovative Medicines Unit
Applying cutting edge genomic techniques to measure biomarkers and further understanding of response and resistance across a range of drug...
PI:
Y
CC:
N
MedImmune
Oncology
Oncology Biologics drug discovery
PI:
Y
CC:
N
Kathryn Chapman is the Executive Manager of the Milner Therapeutics Consortium, a dynamic partnership between pharmaceutical companies and...
PI:
N
CC:
N
ImBio
ImBio
Developing cancer therapy as opposed to research. Autologous tumour-dendritic cell fusion hybrids for cancer therapy
PI:
Y
CC:
N
AstraZeneca, MedImmune
CRUK Cambridge Institute
AstraZeneca Oncology
Oncology
PI:
N
CC:
N
Cancer, DNA Damage, signaling network, mathematics and synergy: what is the connection? Paradoxically, defective cell response to DNA...
PI:
N
CC:
N
University of Cambridge
Department of Physics
My research is concerned with biophysical principles underlying protein aggregation and cell-substrate interactions, with a very strong...
PI:
Y
CC:
University of Cambridge
Department of Biochemistry
Current research aims to generate and functionally validate recombinant antibodies to cell surface receptors, growth factors or signalling...
PI:
N
CC:
University of Cambridge
Department of Pathology
Cancer genetics: application in prognosis and treatment stratification
PI:
N
CC:
N
AstraZeneca
UK trained Clinical Oncologist PhD in Oncology - Vascular Targeting Agents - endothelial cell shape change effects and translational...
PI:
Y
CC:
N
University of Cambridge
Department of Engineering
Main area systems Biology which includes modelling, analysis, and control of biochemical systems. My research is focus on two aspects: 1)...
PI:
Y
CC:
University of Cambridge
Cancer Research UK Cambridge Institute
CRUK Cambridge Institute
I manage the Genomics core facility at the Cambridge Institute; the facility provides services and training, for Cambridge Institute...
PI:
N
CC:
N
MedImmune
Oncology
Cancer Immunotherapy- In vitro profiling of immunostimulatory antibodies as well as elucidation of antibody efficacy and target rationale
PI:
N
CC:
University of Cambridge
Department of Physics
Wellcome Trust CRUK Gurdon Institute, Wellcome Trust MRC Cambridge Stem Cell Institute
My research is concerned with biophysical principles underlying cancer progression and metastasis. As a Research Associate in the groups of...
PI:
N
CC:
Cancer Research UK Cancer Research Technologies (CRT)
Deputy Director of Discovery, Cancer Research Technology Discovery Laboratories
PI:
Y
CC:
N
AstraZeneca
Director, translational science "
Head of department for UK translational science, oncology, AstraZeneca
PI:
N
CC:
N
We work on how the body responds to hypoxia, or low levels of tissue oxygen.  This is relevant to a number of diseases, including cancer,...
PI:
Y
CC:
N
Cancer Research UK Cancer Research Technologies (CRT)
Department of Engineering
Discovery Bioscience
I am a senior group leader at Cancer Research Technology Discovery Laboratories [CRTDL] (a wholly owned subsidiary of Cancer Research UK)....
PI:
N
CC:
N
Cancer Research UK Cancer Research Technologies (CRT)
Cancer Research Technology
Developing novel therapeutics to treat cancer
PI:
N
CC:
University of Cambridge
Department of Engineering
My main research activities focus on the mechanical properties of soft disordered materials, including foams, granular materials, as well...
PI:
Y
CC:
Genestack Limited
Genestack Limited
Genestack was launched in 2012 with a mission to transform genomics big data computing and application engineering. We were founded by...
PI:
N
CC:
Cancer Research UK Cancer Research Technologies (CRT)
The application of Medicinal Chemistry to the design and development of anti-cancer agents.
PI:
N
CC:
University of Cambridge
Wellcome Trust CRUK Gurdon Institute
Tony Kouzarides is Professor of Cancer Biology at the University of Cambridge, Deputy Director of the Gurdon Institute and Director of the...
PI:
Y
CC:
N
University of Cambridge
Department of Chemistry
PI:
Y
CC:
University of Cambridge
Department of Chemistry
Centre for Applied Medical Statistics
later on
PI:
N
CC:
University of Cambridge
I am interested in developing and testing methodologies for modeling biomolecular process (also using bioinformatics and system biology); I...
PI:
Y
CC:
University of Cambridge
Department of Medical Genetics, Department of Materials Science and Metallurgy
My work involves designing electrochemical platform for the Molecularly Engineered Amperometric Recognition Scaffold (MEARS) in bio-sensing...
PI:
N
CC:
Clinical translational research identifying patient selection and PK/PD biomarkers.
PI:
N
CC:
N
University of Cambridge
Department of Medicine
Cambridge Institute for Medical Research
My long standing research interest has involved understanding the genetic basis of susceptibility to autoimmune disease. More recently I...
PI:
N
CC:
MRC Laboratory of Molecular Biology
I have expertise in a wide range of biophysical techniques to characterise protein-protein and protein-ligand interactions to understand...
PI:
N
CC:
Cancer Research UK Cancer Research Technologies (CRT)
Molecular Pharmacology
CRT Discovery Laboratories bridges the gap between academia and industrial drug discovery and development, aiming to validate, de-risk and...
PI:
N
CC:
University of Cambridge
Cancer Research UK Cambridge Institute
* Core bioinformatics support * Analysis of RNA-Seq, ChIP-Seq, expression microrray and mass-spectrometric proteomics data * Data analysis...
PI:
N
CC:
University of Cambridge
Department of Clinical Neuroscience
1: Application of nanotherapy to target endogenous neural stem cells in vivo for treatment of neurodegenerative diseases. 2: Application of...
PI:
Y
CC:
Sareum Ltd
Sareum Ltd
Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, primarily focusing on cancer. Sareum...
PI:
Y
CC:
European Bioinformatics Institute, Wellcome Trust Sanger Institute, University of Cambridge
Department of Computer Laboratory
Bioinformatics Research fellow, Garvan Institute of Medical Research
.
PI:
N
CC:
University of Cambridge
Department of Oncology
CRUK Cambridge Institute
The Murphy Group studied cell surface proteinases that modulate both the extracellular matrix and the activities of key cytokines and...
PI:
Y
CC:
N
University of Cambridge
Department of Chemistry
University of Cambridge
Involved in the chemical synthesis of novel agents.
PI:
Y
CC:
Cambridge University Hospitals NHS Foundation Trust
Department of Oncology
1. screening studies (3) for BRCA1...
PI:
N
CC:
University of Cambridge
Computer Laboratory
I am a Mathematician and I am doing a PhD in bioinformatics at the University if Cambridge. I am currently working on gene network...
PI:
N
CC:
N
MISSION Therapeutics Ltd
MISSION Therapeutics
PI:
N
CC:
University of Cambridge
Department of Engineering
Experimental and computational biomedical engineering.
PI:
Y
CC:
University of Cambridge
Department of Physics
I work on radiotherapy projects with the Department of Oncology, making use of the computing expertise from my High Energy Physics research...
PI:
Y
CC:
University of Cambridge
Department of Chemistry
Organic synthesis - generally related to anticancer natural products and analogues. Synthesis of potent cytotoxic payloads for antibody-...
PI:
Y
CC:
University of Cambridge
MRC Cancer Unit
Hutchison MRC Research Centre
Studying the he cross-talk between tumour and its stromal microenvironment in order to choose the best targeting strategy to promote tumour...
PI:
N
CC:
N
University of Cambridge
Department of Biochemistry
Luca's research focuses on the relationship between cancers and physiological but not homeostatic processes like tissue regeneration and...
PI:
N
CC:
N
DNA damage and repair, oncology clinical biomarkers
PI:
N
CC:
N
MISSION Therapeutics Ltd
Biology
Discovery and development of novel oncology drugs by inhibiting deubiquitylating enzymes within the DNA damage response, expoliting the...
PI:
N
CC:
Kymab Ltd
I trained as a biochemist and molecular/cellular biologist. Initially, my research in academia focused on the mechanisms regulating...
PI:
N
CC:
N
University of Cambridge
Department of Physics
I'm programme co-ordinator for www.voxtox.org and www.accel-rt.org, two interdisciplinary computational radiotherapy research programmes.
PI:
N
CC:
University of Cambridge
Department of Physics
We are interested in the role of stem cells in the maintenance of adult tissue. In particular, by drawing of the results of inducible...
PI:
Y
CC:
University of Cambridge
Department of Chemistry
Developing new cancer therapeutics
PI:
Y
CC:
N
University of Cambridge
Department of Chemistry
Our research interests are centered on using organic synthesis to make small molecules and peptides, which potentially could be used for...
PI:
Y
CC:
University of Cambridge
Department of Engineering
I am interested in developing engineering materials models for soft tissue in collaboration with medical researchers and clinicians and...
PI:
Y
CC:
Cancer Research UK Cancer Research Technologies (CRT)
CRT Discovery Laboratories Cambridge
CRT Discovery Laboratories (CRT-DL) is the in-house drug discovery unit of Cancer Research Technology, the wholly-owned development and...
PI:
N
CC:
N
Wellcome Trust Sanger Institute
Cancer genome project
single cell analysis of cancer cells
PI:
N
CC:
N
University of Cambridge
Department of Biochemistry
My research as part of the Owen-Mott lab is in designing a small peptide therapeutic for Ras driven cancers. Abberant Ras signalling in...
PI:
N
CC:
N
University of Cambridge
Department of Clinical Neuroscience, Department of Engineering
PI:
N
CC:
N
University of Cambridge
Department of Pharmacology
Binding of antibiotics and drugs to DNA.   Development of new anti-cancer drugs.
PI:
Y
CC:
University of Cambridge
Department of Medicine
Cambridge Institute for Medical Research
I am interested in determining how human cytomegalovirus and other intracellular pathogens evade innate immunity. We recently developed ?...
PI:
N
CC:
Y
University of Cambridge
Department of Oncology
  The aim of the Biomarker Initiative is to accelerate a protein biomarker programme in the CRUK Cambridge Institute which is complementary...
PI:
N
CC:
Wellcome Trust Sanger Institute
Cambridge Cancer Centre Executive Committee, Associate Director for Genetics and Genomics
PI:
N
CC:
N
University of Cambridge
Department of Applied Mathematics and Theoretical Physics
Cambridge Computational Biology Institute (CCBI)
Computational and Systems Approaches to Gene Circuits and Networks Controlling Chromosome Segregation and Morphogenesis; Gene Expression...
PI:
N
CC: